However, resistance to tamoxifen contributes to the recurrence of BC for more than 25% of its users, thus justifying the use of second-line drugs, such as selective estrogen receptor degraders (SERDs), or AIs [11]. This evidence concerns the gene ESR1 and breast cancer.